| Total Voting Rights | 01-May-2026 | 07:00 | RNS |
| Admission to Trading | 30-Apr-2026 | 08:15 | RNS |
| Admission to Trading Application | 27-Apr-2026 | 09:51 | RNS |
| Grant of Awards | 08-Apr-2026 | 17:18 | RNS |
| Total Voting Rights | 01-Apr-2026 | 07:00 | RNS |
| 2026 Annual General Meeting notification | 30-Mar-2026 | 15:30 | RNS |
| Preliminary results for the year ended 31 Dec 2025 | 26-Mar-2026 | 07:00 | RNS |
| Admission to Trading | 09-Mar-2026 | 07:53 | RNS |
| Admission to Trading Application | 04-Mar-2026 | 11:45 | RNS |
| Capital Markets Day and investor conferences | 03-Mar-2026 | 07:00 | RNS |
| Total Voting Rights | 02-Mar-2026 | 07:00 | RNS |
| Form 8.5 (EPT/RI)-Replacement of Oxford Biomedica | 27-Feb-2026 | 13:31 | RNS |
| Form 8.3 - Oxford Biomedica plc | 26-Feb-2026 | 15:20 | RNS |
| Form 8.5 (EPT/RI)-Replacement of Oxford Biomedica | 26-Feb-2026 | 13:49 | RNS |
| Form 8.3 - Oxford Biomedica plc | 26-Feb-2026 | 12:33 | RNS |
| Currency | UK Pounds |
| Share Price | 593.00p |
| Change Today | -7.00p |
| % Change | -1.17 % |
| 52 Week High | 913.00 |
| 52 Week Low | 277.00 |
| Volume | 177,958 |
| Shares Issued | 120.92m |
| Market Cap | £717.06m |
| Beta | 0.03 |
| RiskGrade | 125 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 5 |
| Buy | 2 |
| Neutral | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 10 |

| No dividends found |
| Time | Volume / Share Price |
| 16:35 | 1,412 @ 593.00p |
| 16:35 | 526 @ 593.00p |
| 16:35 | 29,389 @ 593.00p |
| 16:35 | 217 @ 593.00p |
| 16:35 | 316 @ 593.00p |
| Chair | Roch Doliveux |
| CEO | Frank Mathias |
| CFO | Lucinda (Lucy) Crabtree |
You are here: research